Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02892357
Other study ID # Digestion-04
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 2017
Est. completion date December 2019

Study information

Verified date February 2019
Source Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contact fengyun Wang, Ph.D
Phone +86-10-62835001
Email wfy811@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind,randomised,placebo-controlled clinical trial.We would like to investigate the safety and efficacy of Jianpi Qinghua granule(a Chinese herbal compound) combined with half-dose omeprazole in treatment of non-erosive reflux disease(NERD).


Description:

This is a double-blind,randomised,placebo-controlled clinical trial.We recruit patients that suffer from non-erosive reflux disease and then divide them into two groups:treatment group and control group.Treatment group take Jianpi Qinghua granule and half-dose omeprazole for 4 weeks,control group take a normal dose of omeprazole for 4 weeks.Finally we investigate the safety of Jianpi Qinghua granule combined with half-dose omeprazole in treatment of non-erosive reflux disease(NERD),and contrast the efficacy of Jianpi Qinghua granule with omeprazole.


Recruitment information / eligibility

Status Recruiting
Enrollment 204
Est. completion date December 2019
Est. primary completion date September 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Aging between 18 and 75 years, able to read and write Chinese;

- Meet the criteria of diagnosis of NERD

- GERD Q score>=8

- Meet the TCM diagnosis of syndrome of dampness-heat due to spleen deficiency

- Receiving no other treatments during the study;

- Voluntarily agreeing with the study protocol and signing a written informed consent.

Exclusion Criteria:

- Gastro-duodenal ulcer

- Infections, inflammations, or obstruction of the small or large intestine

- History of gastrointestinal cancer, or prior surgery of the stomach or intestine

- Females who are pregnant or those lacking adequate contraception

- Unwilling to sign the informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Treatment group
Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
Control group
sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.

Locations

Country Name City State
China Dongfang Hospital Beijing Beijing
China Guanganmen Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of GERD Q Scale GerdQ was developed through the integration of validated questionnaires reflecting psychological problems and the data of diagnoses of GERD in primary and secondary medical institutions. GerdQ is used for the diagnosis and management of GERD with good authenticity and reliability. GerdQ has six items: heartburn, regurgitation, abdominal pain, nausea, sleep disorders and use of OTC medications. The score is evaluated according to the frequency of every item occurred in recent one week. 0 day, 1 day, 2-3 days, 4-7days respectively assessed to the score of 0, 1, 2 and 3 in the items of heartburn, regurgitation, sleep disorders and use of OTC medications. 0 day, 1 day, 2-3 days, 4-7days respectively assessed to the score of 3, 2, 1 and 0 in the items of abdominal pain and nausea. 6 weeks
Secondary Change of TCM Syndrome Questionnaire The scale is based on the Clinical Guideline of New Drugs for Traditional Chinese Medicine. It is uesd to evaluate the discomfort of gastrointestinal system based on TCM theory. It contains 15 items of TCM terminology which used to assess severity of physical discomfort (0 = absent; 1 = mild; 2 = moderate; 3 = severe). The main concerns of these items include stomach distension, stomachache, appetite decrease, heartburn, acid regurgitation, sputum increase, feeling of obstruction in pharynx, feeling thirsty but not want water, feeling of distention on both sides of the lower abdomen, limbs weakness, short of breath, feeling weak and unwilling to speak, somatosensory heaviness, feeling afraid of the cold and having loose stool. 6 weeks
Secondary Change of 36-Item Short Form Survey Instrument(SF-36) SF-36 reflects healthy condition. 6 weeks
Secondary Change of Patients Report Clinical Outcomes(PRO) The PRO was developed by the digestive department of Xiyuan hospital. Considering the clinical characteristics of patients with chronic gastrointestinal diseases in China, we have spended two years to collect measurement indicators, screen and optimizing items, implement pre-survey of small samples and field survey, and finally formulated this current PRO. It contains 35 items in six dimensions (regurgitation, dyspepsia, physical status, ability to life, defecation situation and mental state). Our analysis of 274 questionnaires show that the PRO has good reliability and validity in reflecting the situation of chronic gastrointestinal diseases. Every item in PRO has five levels of discomfort(never, occasionally, sometimes, often, always) and they respectively represent the score of 0, 1, 2, 3 and 4. 6 weeks
Secondary Change of the Hamilton Depression Scale 17 item (HAMD17) The scoring criteria of the scale were :(0)none;(1)mild;(2)moderate;(3)severe;(4) extremely heavy.A few items use the 3-grade scoring method with 0-2 points, and the grading standard is :(0) none;(1) mild to moderate;(2) severely. 6 weeks
Secondary Safety outcomes Safty indexs contain adverse event, general medical examination, blood biochemical examination, urine and stool routine test and electrocardiography. 6 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05587322 - A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease Phase 3
Completed NCT02556021 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease Phase 3
Completed NCT03444883 - Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD Phase 3
Completed NCT03591653 - A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks Phase 3
Completed NCT00562094 - Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS) N/A
Completed NCT00259077 - Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population Phase 3
Enrolling by invitation NCT02149914 - The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients N/A
Terminated NCT00449813 - The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511) Phase 4
Completed NCT02081404 - Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study N/A
Completed NCT01797939 - Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients N/A
Recruiting NCT04255693 - Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence N/A
Recruiting NCT04252144 - Study of Dietary Patterns and Food Diversity in Russian GERD Patients N/A
Completed NCT01750437 - Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD) Phase 2
Completed NCT01560910 - Detection of Minimal Change Esophagitis by I-scan N/A
Completed NCT00830115 - Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders N/A
Completed NCT00259051 - A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population Phase 3
Not yet recruiting NCT04759378 - Comorbid Esophageal Disorders in IBS Patients N/A
Recruiting NCT05369884 - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D Early Phase 1
Recruiting NCT06121830 - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD) Phase 3
Terminated NCT02788591 - Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection N/A